Inflammation/Immunology

PDE4 ligand 2 is a CRBN E3 ligase ligand. PDE4 ligand 2 can be used to synthesize PROTAC such as PDE4 degrader-1 (HY-174405). PDE4 ligand 2 can be studied in research for autoimmune and anti-inflammatory diseases.

(22E,24R)-23-Methylergosta-7,22-diene-3β,5α,6β-triol (Compound 7) is an Ergosteroid. (22E,24R)-23-Methylergosta-7,22-diene-3β,5α,6β-triol can be isolated from Penicillium herquei. (22E,24R)-23-Methylergosta-7,22-diene-3β,5α,6β-triol exhibits no obvious inhibitory activities against NO production induced by LPS.

Isogosferol ((+)-Isogospherol; Isogospherol) is a potent anti-inflammatory agent. Isogosferol decreases LPS (HY-D1056)-stimulated NO and IL-1β expression. Isogosferol decreases the LPS (HY-D1056)-stimulated expression of iNOS, COX-2, NF-κB, and pERK1/2.

Conagenin is an immunomodulator. Conagenin shows antitumor effects by activation of T cells and increasing antitumor effector cells.

Landiolol-d₈ (ONO1101-d₈) is the deuterium labeled Landiolol (HY-100607). Landiolol (ONO1101) is a highly selective, ultra-short-acting competitive inhibitor of β₁ adrenergic receptors. Landiolol specifically blocks cardiac β₁ receptors, reducing heart rate and myocardial oxygen consumption. Landiolol inhibits TNF-α-induced excessive mitochondrial oxygen consumption and reactive oxygen species production in a sepsis model, alleviating renal injury. Landiolol has little effect on cardiac ion channels (such as L-type calcium current and inward rectifier potassium current) and has a weak negative inotropic effect. Landiolol can be used for perioperative tachycardia control and protection studies of sepsis-related acute kidney injury.

HCV Peptide (131-140) is a peptide. HCV Peptide (131-140) can be used for the research of hepatitis C virus (HCV) .

Triamcinolone diacetate is a synthetic derivative of glucocorticoid. Triamcinolone diacetate has anti-inflammatory activity. Triamcinolone diacetate can be used in research on dermatomyositis, Bell's palsy and rheumatoid arthritis.

MB-311 is a humanized antibody expressed in CHO cells, targeting Lewis Y. MB-311 has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for MB-311 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

IL-17-IN-7 (Compound 23) is a IL-17 inhibitor with a pIC₅₀ of 7.1 against IL-17A.

PPARα/δ agonist 2 (compound 14) is a potent PPARα and PPARδ agonist with EC₅₀s of 3255 nM and 1475 nM for human PPARα and PPARβ/δ, respectively. PPARα/δ agonist 2 shows anti-inflammatory effects.

1,7-Diphenyl-4-hepten-3-one, isolated from Alpinia officinarum, possess bioactivities against some pests, such as T. castaneum.

IRAK4-IN-28 (compound 42) is an orally active IRAK4 inhibitor (IC₅₀=8.9 nM). IRAK4-IN-28 has binding affinity for IRAK4 with a Kd of 0.58 nM. IRAK4-IN-28 can be used in the research of inflammation and autoimmune diseases.

JAK3 covalent inhibitor-2 (compound J1b) is a selective, orally potent JAK3 inhibitor (IC₅₀=7.2 nM) with low toxicity, anti-inflammatory activity and good bioavailability.

NF-κB-IN-20 is an orally active NF-κB inhibitor. NF-κB-IN-20 directly binds to the Keap1 protein, activating the Keap1/Nrf2/HO-1 antioxidant pathway, and simultaneously inhibiting the NF-κB inflammatory pathway, thereby synergistically reducing oxidative stress and inflammatory responses. NF-κB-IN-20 M11 inhibits the expression of IL-6, IL-1β, and TNF-α, significantly reduces the level of ROS, and restores the mitochondrial membrane potential. NF-κB-IN-20 can be used for the study of acute lung injury (ALI).

Lansoprazole (Standard) is the analytical standard of Lansoprazole. This product is intended for research and analytical applications. Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).

Human IgM, Isotype Control is an isotype control for?Human IgM.

LC-MI-3 is an orally active IRAK4 PROTAC degrader with an IC₅₀ of 57.2 nM and high selectivity among human protein kinases. LC-MI-3 eliminates IRAK4 kinase and scaffolding functions via the cereblon E3 ubiquitin ligase and ubiquitin-proteasome systems. LC-MI-3 inhibits downstream nuclear factor-κB and IRAK4-mediated inflammatory signaling pathways. LC-MI-3 can be used for the research of acute lung injury, sepsis, psoriasis, and inflammatory diseases.

CDK8-IN-15 (Compound 46) is a potent CDK8 inhibitors with an IC₅₀ value of 57 nM. It can enhance the thermal stability of CDK8 along with inhibition against NF-κB and have favourable selectivity across the CDK family and tyrosine kinase. Additionally, it also demostrates a positive effect in vitro psoriasis model induced by TNF-α and alleviats the inflammatory response enhancing the expression of Foxp3 and IL-10, which is promising for research of psoriasis diseases.

K-14585 is a peptide competitive PAR2 antagonist. K-14585 inhibits PAR2-dependent IL-8 production, NF-κB phosphorylation, and p38 signaling. K-14585 reduces SLIGKV (PAR2 agonist peptide)-induced Ca²⁺ mobilisation in primary human keratinocytes.

Xenin-8 acetate is the C-terminal octapeptide fragment of xenin, which belongs to the xenopsin family of peptides. Xenin-8 acetate stimulates basal insulin secretion, dose-dependently enhances glucose (EC₅₀ = 0.16 nM) and arginine-induced insulin release, and enhances arginine- and Carbamoylcholine chloride (HY-B1208)-induced glucagon secretion. Xenin-8 acetate antagonizes the inhibition of glucagon release by elevated glucose. Xenin-8 acetate can be used in research on type 2 diabetes and obesity-related glucose metabolic disorders.